Kathryn Haviland
Chief Executive Officer at BLUEPRINT MEDICINES CORPORATION
Net worth: 15 M $ as of 30/03/2024
Profile
Kathryn Haviland is on the board of Fulcrum Therapeutics, Inc. and Chief Operating Officer at Blueprint Medicines Corp., Member of Harvard Business School Health Industry Alumni Association and Member of Biopharma Executive Council. Ms. Haviland previously occupied the position of Vice President-Rare Diseases at Idera Pharmaceuticals, Inc., Head-Commercial Development at Sarepta Therapeutics, Inc. and Executive Director-Commercial Development at PTC Therapeutics, Inc. She received an undergraduate degree from Wesleyan University and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 06/03/2024 | 153,177 ( 0.25% ) | 15 M $ | 30/03/2024 | |
| 26/06/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Kathryn Haviland active positions
| Companies | Position | Start |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Executive Officer | 03/04/2022 |
| FULCRUM THERAPEUTICS, INC. | Chairman | 09/01/2022 |
| Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 15/10/2023 |
Former positions of Kathryn Haviland
| Companies | Position | End |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 30/11/2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 31/03/2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 31/05/2012 |
Training of Kathryn Haviland
| Wesleyan University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
| Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
- Stock Market
- Insiders
- Kathryn Haviland
